NCT07340411 Effect of Chinese Herbal Medicine Nasal Irrigation on the Postoperative Care of Chronic Rhinosinusitis
| NCT ID | NCT07340411 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Taichung Veterans General Hospital |
| Condition | Chronic Rhinosinusitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2023-07-05 |
| Primary Completion | 2026-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 80 participants in total. It began in 2023-07-05 with a primary completion date of 2026-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Investigators tried to evaluate the efficacy and safety of Chinese herbal medicine nasal irrigation as an adjuvant therapy after FESS.
Eligibility Criteria
Inclusion Criteria: * 1\. Patients with chronic rhinosinusitis who failed medical treatment 2.Patients underwent bilateral primary functional endoscopic sinus surgery. Exclusion Criteria: * 1\. Patients with a history of immunodeficiency 2.Patients with a history of sinus surgery 3.Patients who receiving antibiotic treatment within a week before functional endoscopic sinus surgery 4.Patients with a pathological diagnosis of fungal sinusitis 5.Patients with a pathological diagnosis of sinonasal tumor
Contact & Investigator
Rong-San Jiang, MD, PhD
PRINCIPAL INVESTIGATOR
Taichung Veterans General Hospital
Frequently Asked Questions
Who can join the NCT07340411 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Chronic Rhinosinusitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07340411 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07340411 currently recruiting?
Yes, NCT07340411 is actively recruiting participants. Contact the research team at rsjiang@vghtc.gov.tw for enrollment information.
Where is the NCT07340411 trial being conducted?
This trial is being conducted at Taichung, Taiwan.
Who is sponsoring the NCT07340411 clinical trial?
NCT07340411 is sponsored by Taichung Veterans General Hospital. The principal investigator is Rong-San Jiang, MD, PhD at Taichung Veterans General Hospital. The trial plans to enroll 80 participants.